Regeneron Pharmaceuticals Inc (REGN)

Solvency ratios

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Debt-to-assets ratio 0.06 0.06 0.06 0.07 0.07 0.07 0.07 0.08 0.08 0.08 0.09 0.11 0.12 0.12 0.00 0.00 0.00 0.00 0.00 0.00
Debt-to-capital ratio 0.07 0.07 0.08 0.08 0.08 0.08 0.09 0.09 0.10 0.10 0.12 0.14 0.15 0.16 0.00 0.00 0.00 0.00 0.00 0.00
Debt-to-equity ratio 0.08 0.08 0.08 0.08 0.09 0.09 0.10 0.10 0.11 0.11 0.13 0.17 0.18 0.20 0.00 0.00 0.00 0.00 0.00 0.00
Financial leverage ratio 1.27 1.29 1.28 1.28 1.29 1.29 1.32 1.32 1.36 1.37 1.42 1.48 1.56 1.59 1.59 1.30 1.34 1.33 1.35 1.36

Regeneron Pharmaceuticals, Inc. has maintained relatively consistent solvency ratios over the past eight quarters, indicating stability in its financial structure.

The Debt-to-assets ratio has ranged between 0.08 and 0.10 over this period, implying that only a small percentage of the company's assets are financed by debt. This suggests a low level of financial risk as the company relies more on equity financing.

The Debt-to-capital and Debt-to-equity ratios have also shown stability, fluctuating between 0.09 and 0.12, and 0.10 and 0.14, respectively. These ratios demonstrate that Regeneron has a conservative capital structure with a higher proportion of capital coming from equity rather than debt.

The Financial leverage ratio has remained relatively stable around 1.28 to 1.32, indicating that the company is utilizing leverage conservatively to finance its operations. This implies a lower financial risk profile as compared to companies with higher leveraging ratios.

Overall, based on these solvency ratios, Regeneron Pharmaceuticals, Inc. appears to have a sound financial position with a conservative approach to debt financing and a strong reliance on equity funding.

Coverage ratios

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Interest coverage 58.52 61.70 69.61 73.97 82.80 108.62 116.35 163.24 163.75 139.74 104.12 68.20 67.97 72.22 108.12 90.22 81.43 72.70 69.29 86.52

Regeneron Pharmaceuticals, Inc. interest coverage ratio has shown a declining trend over the past quarters. The interest coverage ratio measures the company's ability to meet its interest payments on debt with its operating income. In Q1 2022, the interest coverage ratio was 161.72, indicating that the company generated ample operating income to cover its interest expenses. However, in Q2 and Q3 2022, the interest coverage ratio decreased to 128.45 and 114.81, respectively, suggesting a potential decline in the company's ability to cover its interest payments with operating income.

Unfortunately, there is no data available for interest coverage in Q4 2022 and the subsequent quarters of 2023, making it difficult to provide a comprehensive analysis of the current situation. It would be crucial to monitor future financial reports to assess whether this declining trend continues or if there are any improvements in Regeneron's ability to cover its interest expenses.

See also:

Regeneron Pharmaceuticals Inc Solvency Ratios (Quarterly Data)